Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$2.54 USD
+0.10 (4.10%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Puma Biotech (PBYI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$5.50 | $7.00 | $4.00 | 125.41% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Puma Biotech comes to $5.50. The forecasts range from a low of $4.00 to a high of $7.00. The average price target represents an increase of 125.41% from the last closing price of $2.44.
Analyst Price Targets (2 )
Broker Rating
Puma Biotech currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 3.00 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, one is Strong Buy, representing 33.33% of all recommendations. A month ago, Strong Buy represented 33.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/PBYI.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/3/2024 | H.C. Wainwright & Co. | Edward White | Strong Buy | Strong Buy |
5/3/2024 | Not Identified | Not Identified | Not Available | Strong Sell |
4/1/2024 | Cowen & Co. | Marc Frahm | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 3 |
Average Target Price | $5.50 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | 0.30 |